Assessing Hansoh Pharmaceutical Group (SEHK:3692) Valuation After EU Approval For Aumolertinib Mesylate Tablets

Simply Wall St.03-01

AdvertisementWhat the EU approval could mean for Hansoh Pharmaceutical Group (SEHK:3692) The European Commission’s approval of Hansoh Pharmaceutical Group (SEHK:3692)’s Aumolertinib Mesylate Tablets ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616873305?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-03-01 21:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616873305","market":"sg","top_or_hot":-1,"title":"Assessing Hansoh Pharmaceutical Group (SEHK:3692) Valuation After EU Approval For Aumolertinib Mesylate Tablets","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhat the EU approval could mean for Hansoh Pharmaceutical Group (SEHK:3692) The European Commission’s approval of Hansoh Pharmaceutical Group (SEHK:3692)’s Aumolertinib Mesylate Tablets ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/assessing-hansoh-pharmaceutical-group-sehk3692-valuation-aft\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Hansoh Pharmaceutical Group (SEHK:3692) Valuation After EU Approval For Aumolertinib Mesylate Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Hansoh Pharmaceutical Group (SEHK:3692) Valuation After EU Approval For Aumolertinib Mesylate Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-01 21:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/assessing-hansoh-pharmaceutical-group-sehk3692-valuation-aft><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhat the EU approval could mean for Hansoh Pharmaceutical Group (SEHK:3692) The European Commission’s approval of Hansoh Pharmaceutical Group (SEHK:3692)’s Aumolertinib Mesylate Tablets ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/assessing-hansoh-pharmaceutical-group-sehk3692-valuation-aft\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/assessing-hansoh-pharmaceutical-group-sehk3692-valuation-aft","article_id":"2616873305","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/assessing-hansoh-pharmaceutical-group-sehk3692-valuation-aft","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616873305","pubTimestamp":1772370964,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"What the EU approval could mean for Hansoh Pharmaceutical Group (SEHK:3692)\nThe European Commission’s approval of Hansoh Pharmaceutical Group (SEHK:3692)’s Aumolertinib Mesylate Tablets for specific advanced non small cell lung cancer patients takes Ameile and Aumseqa beyond China and into a major new market.\nThis decision, following a positive view from the European Medicines Agency’s Committee for Medicinal Products for Human Use, adds an EU indication for both first line EGFR mutated NSCLC...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1589":"北水核心资产","BK4156":"煤与消费用燃料","BK1191":"制药","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","03692":"翰森制药"},"translate_title":"评估豪森药业集团（SEHK：3692）甲磺酸奥莫替尼片在欧盟批准后的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9,"DCF":1},"content_text":"AdvertisementWhat the EU approval could mean for Hansoh Pharmaceutical Group (SEHK:3692) The European Commission’s approval of Hansoh Pharmaceutical Group (SEHK:3692)’s Aumolertinib Mesylate Tablets for specific advanced non small cell lung cancer patients takes Ameile and Aumseqa beyond China and into a major new market. This decision, following a positive view from the European Medicines Agency’s Committee for Medicinal Products for Human Use, adds an EU indication for both first line EGFR mutated NSCLC and EGFR T790M mutation positive disease. See our latest analysis for Hansoh Pharmaceutical Group. At around HK$34.96, Hansoh Pharmaceutical Group’s recent 1 day share price return of 2.22% sits against a weaker 30 day share price return of a 9.19% decline, while its 1 year total shareholder return of 96.18% and 3 year total shareholder return of 139.14% point to strong longer term momentum. If this EU approval has you looking across the oncology space, it could be a good moment to see what else is gaining attention through our screener of 113 healthcare AI stocks. With revenue growth running at about 11.8% and net income growth around 12.4%, plus the shares sitting roughly 28% below an intrinsic estimate and 34% below analyst targets, is Hansoh a mispriced growth story, or is the market already factoring all this in? Price-to-Earnings of 38.8x: Is it justified? Hansoh Pharmaceutical Group trades on a P/E of 38.8x, which sits well above its own estimated fair P/E of 26x and the wider Hong Kong Pharmaceuticals industry at 13.2x. The P/E ratio compares the current share price to earnings per share, so at 38.8x you are paying a higher price for each unit of earnings than for many peers in the sector. That premium sits alongside several facts investors may weigh together, including 5 year earnings growth of 14.8% per year, a forecast earnings growth rate of 12.42% per year, and revenue growth projected at 11.8% per year compared to 8.6% for the Hong Kong market. The fair P/E estimate of 26x points to a level the market could move towards if sentiment around growth and quality converges with this model. Against the local Pharmaceuticals industry average P/E of 13.2x and a peer average of 22.4x, Hansoh’s 38.8x multiple stands out as materially richer. This implies the market is attaching a higher value to its earnings profile than to many industry names. Explore the SWS fair ratio for Hansoh Pharmaceutical Group Result: Price-to-Earnings of 38.8x (OVERVALUED) However, you still need to watch for setbacks in EU commercialization, as well as any change in expectations around that 38.8x P/E premium to peers. Find out about the key risks to this Hansoh Pharmaceutical Group narrative. Another way to look at value While the 38.8x P/E suggests Hansoh Pharmaceutical Group is expensive relative to a 26x fair ratio and peers, our DCF model points the other way. On that view, the shares trade about 28.3% below an estimated fair value of roughly HK$48.77. This raises a simple question: which signal do you trust more? Look into how the SWS DCF model arrives at its fair value. 3692 Discounted Cash Flow as at Mar 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Hansoh Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 218 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If the mixed signals on valuation leave you unsure, do not sit on the fence. Review the data yourself and see what stands out in the 4 key rewards. Looking for more investment ideas? If Hansoh has sharpened your focus, do not stop here. Broaden your watchlist now so you are not relying on a single opportunity.  Target potential bargains by checking companies our screener flags as 218 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect them. Strengthen your income corner by reviewing 448 dividend fortresses that could help anchor your portfolio with sizeable yields. Sleep easier by focusing on resilience first and reviewing 322 resilient stocks with low risk scores that our models score as comparatively less exposed.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Hansoh Pharmaceutical Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616873305","isCrawlerRequest":true}